Date : May 8, 2023
Global Pharma Labs, Inc. (“Labs”) and GPL Holdings , Inc. (“GPLL”) entered into a Letter of Intent to merge whereas the shareholders of Labs would become shareholders of GPLL. The resulting merger would result in Labs becoming a wholly owned subsidiary of GPLL.
Additionally, Global Pharma Labs, Inc. has recently entered into an agreement with a clinical research organization (CRO) to begin clinical trials in India on OA-sys ,a new antiarthritic drug, in the treatment of osteo /infectious arthritis.
Global Pharma Labs, Inc. has also recently partnered with VDGPL in Zambia , which has now opened a wholesale pharmaceutical facility in Lusaka, Zambia.
We believe the anticipated merger by and between Labs and GPLL will offer benefit to the shareholders of both entities and will further distinguish both companies in the United States and internationally.
This press release contains forward-looking statements. There are risks and
uncertainties. The actual outcome of the anticipated merger could materially differ from that contemplated by management.